William Phd Link Sells 12,500 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Director William Phd Link sold 12,500 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $68.79, for a total transaction of $859,875.00. Following the sale, the director owned 116,332 shares in the company, valued at approximately $8,002,478.28. This trade represents a 9.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Tarsus Pharmaceuticals Stock Performance

TARS stock traded down $1.55 during midday trading on Wednesday, reaching $68.24. The company had a trading volume of 472,267 shares, compared to its average volume of 597,192. The firm has a market capitalization of $2.90 billion, a PE ratio of -42.12 and a beta of 0.55. The stock has a 50 day moving average price of $69.79 and a 200 day moving average price of $70.21. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $38.51 and a fifty-two week high of $85.25. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The company had revenue of $151.67 million for the quarter, compared to analyst estimates of $144.56 million. Analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

TARS has been the topic of several recent research reports. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday. Zacks Research cut Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. The Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Finally, Mizuho began coverage on Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $91.83.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. RTW Investments LP boosted its stake in Tarsus Pharmaceuticals by 5.0% during the 4th quarter. RTW Investments LP now owns 3,335,320 shares of the company’s stock valued at $273,096,000 after purchasing an additional 157,884 shares in the last quarter. Deep Track Capital LP raised its stake in shares of Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after buying an additional 1,250,000 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 5.5% in the third quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock valued at $154,790,000 after buying an additional 136,582 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 5.6% in the fourth quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock valued at $196,476,000 after buying an additional 127,470 shares during the period. Finally, Morgan Stanley boosted its stake in Tarsus Pharmaceuticals by 6.7% during the fourth quarter. Morgan Stanley now owns 2,040,742 shares of the company’s stock valued at $167,096,000 after buying an additional 128,340 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.